Glycocalyx Monitoring in Major Abdominal Surgery (GLYCOCHIP)

May 21, 2026 updated by: University Hospital, Rouen

Evaluation of Perioperative Glycocalyx Monitoring in Major Abdominal Surgery

The study of the microcirculation and glycocalyx could be an essential element in the monitoring of our patients undergoing major abdominal surgery. It would enable us to better target the objectives of anaesthesia and resuscitation, which until now have been based essentially on macro-circulatory parameters.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This monitoring is possible in real time and real conditions by micro-camera GlycoCheck™ (Microvascular Health Solutions Inc., Salt Lake City, Utah, USA), a non-invasive monitoring allowing the study of sublingual microcirculation and glycocalyx.

Study Type

Observational

Enrollment (Actual)

78

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Rouen, France, 76000
        • Rouen University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Patient undergoing major abdominal surgery by cytoreduction combined with an intraperitoneal chemotherapy bath (HIPEC) or cephalic duodeno-pancreatectomy (CDP) with epidural analgesia planned in accordance with the department's usual practice

Description

Inclusion Criteria:

For the HIPEC group :

  • Adult patients
  • Age < 75 years
  • Receiving HIPEC for primary or secondary peritoneal carcinosis

For the CDP group :

  • Adult patient
  • Age < 75 years
  • Receiving CDP for pancreatic neoplasia
  • Patient who has read and understood the information letter and does not object to taking part in the study
  • Patient affiliated to a social security scheme

Exclusion Criteria:

  • Secondary distant peritoneal metastases
  • Chronic heart failure
  • Chronic liver failure at stage C of the Child-Pugh score
  • Stage IV or V chronic renal failure
  • Inflammation of the sublingual buccal mucosa or injury that may locally influence sublingual microcirculation
  • Patient refusal
  • Person deprived of liberty by an administrative or judicial decision or person placed under court protection or guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group HIPEC
Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC)
Procedure: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
Other Names:
  • HIPEC
Group CDP
Cephalic DuodenoPancreatectomy (CDP)
Procedure: Cephalic DuodenoPancreatectomy
Cephalic DuodenoPancreatectomy
Other Names:
  • CDP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycocalyx thickness
Time Frame: between the day before the operation (Day -1) and the post-operative period (Day 1)
Perioperative variation in glycocalyx thickness (µm)
between the day before the operation (Day -1) and the post-operative period (Day 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycocalyx thickness and a biological marker of tissue hypoperfusion
Time Frame: post-operative period (Day 1)
To assess, in each population ((HIPEC and CDC), the association between the thickness of the glycocalyx established by analysis of the sublingual microcirculation using GlycoCheck® and a biological marker of tissue hypoperfusion.
post-operative period (Day 1)
Glycocalyx thickness and a biological marker of tissue hypoxia
Time Frame: post-operative period (Day 1)
Establish the link between glycocalyx thickness and a biological marker of tissue hypoxia.
post-operative period (Day 1)
Blood cell velocity and macrocirculatory function
Time Frame: post-operative period (Day 1)
Assess the association between velocity of the red blood cells (µm/s) and cardiac index obtained by Most-Care® monitoring on Day 1.
post-operative period (Day 1)
Perfused capillary density and macrocirculatory function
Time Frame: post-operative period (Day 1)
Assess the association between perfused capillary density (mm/mm2) and cardiac index obtained by Most-Care® monitoring on Day 1.
post-operative period (Day 1)
Variation of glycocalyx thickness and the daily entry-exit balance (BES) Day 1
Time Frame: between Day -1 and Day 1
To assess the difference between water and fluid intake (perfusion, nutrition, drug dilution solution) and output (diuresis, digestive aspiration, diarrhoea) over 24 hours
between Day -1 and Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Investigators

  • Principal Investigator: Zoé DEMAILLY, Dr, University Rouen Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 5, 2022

Primary Completion (Actual)

March 3, 2025

Study Completion (Actual)

May 13, 2026

Study Registration Dates

First Submitted

January 2, 2024

First Submitted That Met QC Criteria

February 22, 2024

First Posted (Actual)

February 29, 2024

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023/0046/OB
  • 2023-A00350-45 (Registry Identifier: French Minister)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Abdominal Surgery

Clinical Trials on Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe